Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 479 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer January 26, 2021 A Novel Model Helps Better Predict Risk of Cancer Development in... April 15, 2024 Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... September 10, 2022 Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 July 6, 2026 Load more HOT NEWS Breast Cancer Patient Devotes Her Time to Driving Others to Treatment The UK Government’s spending review: Time to invest in the future... Approximately 1 Million of New Maternal Orphans Due to Cancer in... How to Talk With Your Children About Your Metastatic Cancer Prognosis
